IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Company/Organization Date Area of
Collaboration
Fujisawa 2000 Impotence, obesity
and baldness
IPF Pharmaceuticals
GmbH
Terms of Agreement
Collaboration for the development of
products for male impotence, obesity and
baldness, as well as other conditions
common in aging men. It was the first
deal of its kind between two Japanese
companies. Takeda will begin clinical trials
of the compounds through TAP in the US.
Fujisawa will then use the clinical data for
approval in Japan.
2000 Peptidomics Long-term research collaboration with TAP
for research into natural human peptides,
for the identification of new drug targets
and candidates.
Various 2000 SNPs 43 Japanese and international companies
formed the Pharma SNP Consortium, for
the research of SNP data relevant to the
Japanese population. Being coordinated by
the Japan Pharma Manufacturers’ Assoc.,
it will have Yen1 billion of funding over
three years. The group will examine SNPs
from 1,000 Japanese to build a database
to help in developing drugs tailored for the
domestic population.
Pharmacopeia/MSI 2000 Crystal structure Takeda joined MSI’s Pharmaceutical
Development Consortium, for the creation
of new computational methods to examine
crystal structures and predict properties of
drugs.
Taisho 2000 International R&D
collaboration
Takeda agreed to run international clinical
trials of Taisho’s drugs. Takeda will have
priority to negotiate exclusive marketing
rights to target drug candidates. Target
territories are North America and Europe.
Affymetrix 1999 GeneChip Affymetrix granted Takeda access to its
GeneChip technology.
© 2009 IMS Health In cor po rated or its af fil i ates Page 106